India · Delayed Price · Currency is INR Panacea Biotec Statistics
Total Valuation
Panacea Biotec has a market cap or net worth of INR 27.00 billion. The enterprise value is 26.08 billion.
| Market Cap | 27.00B |
| Enterprise Value | 26.08B |
Important Dates
The next estimated earnings date is Wednesday, November 12, 2025.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Panacea Biotec has 61.25 million shares outstanding. The number of shares has decreased by -0.66% in one year.
| Current Share Class | 61.25M |
| Shares Outstanding | 61.25M |
| Shares Change (YoY) | -0.66% |
| Shares Change (QoQ) | +0.65% |
| Owned by Insiders (%) | 68.70% |
| Owned by Institutions (%) | 0.11% |
| Float | 15.42M |
Valuation Ratios
The trailing PE ratio is 234.93.
| PE Ratio | 234.93 |
| Forward PE | n/a |
| PS Ratio | 4.43 |
| PB Ratio | 3.25 |
| P/TBV Ratio | 3.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 227.16 |
| EV / Sales | 4.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.29 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -3.47% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 2.84M |
| Profits Per Employee | 53,420 |
| Employee Count | 2,149 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Panacea Biotec has paid 45.40 million in taxes.
| Income Tax | 45.40M |
| Effective Tax Rate | 28.99% |
Stock Price Statistics
The stock price has increased by +43.47% in the last 52 weeks. The beta is 0.30, so Panacea Biotec's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +43.47% |
| 50-Day Moving Average | 422.68 |
| 200-Day Moving Average | 429.40 |
| Relative Strength Index (RSI) | 55.08 |
| Average Volume (20 Days) | 201,477 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Panacea Biotec had revenue of INR 6.10 billion and earned 114.80 million in profits. Earnings per share was 1.88.
| Revenue | 6.10B |
| Gross Profit | 3.75B |
| Operating Income | -475.70M |
| Pretax Income | 156.60M |
| Net Income | 114.80M |
| EBITDA | -125.90M |
| EBIT | -475.70M |
| Earnings Per Share (EPS) | 1.88 |
Balance Sheet
The company has 1.10 billion in cash and 222.10 million in debt, giving a net cash position of 879.10 million or 14.35 per share.
| Cash & Cash Equivalents | 1.10B |
| Total Debt | 222.10M |
| Net Cash | 879.10M |
| Net Cash Per Share | 14.35 |
| Equity (Book Value) | 8.31B |
| Book Value Per Share | 136.92 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 61.47%, with operating and profit margins of -7.80% and 1.88%.
| Gross Margin | 61.47% |
| Operating Margin | -7.80% |
| Pretax Margin | 2.57% |
| Profit Margin | 1.88% |
| EBITDA Margin | -2.06% |
| EBIT Margin | -7.80% |
| FCF Margin | n/a |
Dividends & Yields
Panacea Biotec does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.66% |
| Shareholder Yield | 0.66% |
| Earnings Yield | 0.43% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |